Vedolizumab
Takeda
['crohn']
ferrante - rw comparison of vdz-ustk for bio-na ve #crohns showing similar (and incredibly good) clinical and endoscopic outcomes at 1-3 years after risk matching. treatment persistence better with ustk. surprising results like this is why we need hq comparative trials #ddw2023 
Swedish physician specializing in the treatment of Crohn's disease and Ulcerative Colitis. Views - my own.